Sze Ling Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9227074/publications.pdf

Version: 2024-02-01

840119 887659 22 321 11 17 citations h-index g-index papers 22 22 22 686 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. British Journal of Clinical Pharmacology, 2016, 82, 1636-1646.	1.1	67
2	Establishing multiple omics baselines for three Southeast Asian populations in the Singapore Integrative Omics Study. Nature Communications, 2017, 8, 653.	5.8	39
3	Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS ONE, 2017, 12, e0186200.	1.1	36
4	Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. Pharmacogenomics, 2015, 16, 1161-1178.	0.6	25
5	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations. Pharmacogenetics and Genomics, 2016, 26, 28-39.	0.7	21
6	World's First Experience Treating TASC II C and D Tibial Occlusive Disease Using the Selution SLR Sirolimus-Eluting Balloon: Six-Month Results From the PRESTIGE Study. Journal of Endovascular Therapy, 2021, 28, 555-566.	0.8	17
7	Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. Pharmacogenomics, 2017, 18, 891-910.	0.6	15
8	Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics Journal, 2019, 19, 401-410.	0.9	15
9	Early results of an Asian prospective multicenter VenaSeal real-world postmarket evaluation to investigate the efficacy and safety of cyanoacrylate endovenous ablation for varicose veins. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 335-345.e2.	0.9	14
10	Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population. Pharmacogenetics and Genomics, 2011, 21, 35-41.	0.7	13
11	Two-year clinical outcomes following lower limb endovascular revascularisation for chronic limb-threatening ischaemia at a tertiary Asian vascular centre in Singapore. Singapore Medical Journal, 2022, 63, 79-85.	0.3	12
12	The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Pharmacogenomics, 2012, 13, 1247-1256.	0.6	7
13	Time course and clinical characterization of cisplatinâ€induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. Head and Neck, 2018, 40, 1425-1433.	0.9	7
14	Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multiethnic Asian population. Thrombosis and Haemostasis, 2011, 105, 1100-1102.	1.8	5
15	Use of Paclitaxel Coated Drug Eluting Technology to Improve Central Vein Patency for Haemodialysis Access Circuits: Any Benefit?. Vascular Specialist International, 2020, 36, 21-27.	0.2	5
16	Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public. Personalized Medicine, 2013, 10, 127-137.	0.8	4
17	ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC. International Journal of Technology Assessment in Health Care, 2014, 30, 113-120.	0.2	4
18	The art and science of achieving zero COVID-19 transmissions in staff at a large community care facility in Singapore using implementation science: a retrospective analysis. F1000Research, 0, 10, 212.	0.8	4

#	Article	IF	CITATIONS
19	Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. British Journal of Clinical Pharmacology, 2021, 87, 886-894.	1.1	3
20	Effect of fertility health awareness strategies on fertility knowledge and childbearing in young married couples (FertStart): study protocol for an effectiveness-implementation hybrid type I multicentre three-arm parallel group open-label randomised clinical trial. BMJ Open, 2022, 12, e051710.	0.8	3
21	12-Months Results From the PRESTIGE Study Using Sirolimus Drug-Eluting Balloons in the Treatment of Complex BTK Tibial Atherosclerotic Lesions in CLTI Patients. Cardiovascular Revascularization Medicine, 2022, 43, 143-146.	0.3	3
22	Utility of a novel high pressure non-compliant balloon for tibial atherosclerotic lesions in Asian patients with chronic limb threatening ischaemia. Vasa - European Journal of Vascular Medicine, 2020, 49, 475-482.	0.6	2